| Literature DB >> 33827580 |
Yu-Chen S H Yang1, Po-Jui Ko2,3, Yi-Shin Pan4, Hung-Yun Lin5,6,7,8,9, Jacqueline Whang-Peng10,11, Paul J Davis12,13, Kuan Wang4.
Abstract
Thyroid hormone analogues-particularly, L-thyroxine (T4) has been shown to be relevant to the functions of a variety of cancers. Integrin αvβ3 is a plasma membrane structural protein linked to signal transduction pathways that are critical to cancer cell proliferation and metastasis. Thyroid hormones, T4 and to a less extend T3 bind cell surface integrin αvβ3, to stimulate the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway to stimulate cancer cell growth. Thyroid hormone analogues also engage in crosstalk with the epidermal growth factor receptor (EGFR)-Ras pathway. EGFR signal generation and, downstream, transduction of Ras/Raf pathway signals contribute importantly to tumor cell progression. Mutated Ras oncogenes contribute to chemoresistance in colorectal carcinoma (CRC); chemoresistance may depend in part on the activity of ERK1/2 pathway. In this review, we evaluate the contribution of thyroxine interacting with integrin αvβ3 and crosstalking with EGFR/Ras signaling pathway non-genomically in CRC proliferation. Tetraiodothyroacetic acid (tetrac), the deaminated analogue of T4, and its nano-derivative, NDAT, have anticancer functions, with effectiveness against CRC and other tumors. In Ras-mutant CRC cells, tetrac derivatives may overcome chemoresistance to other drugs via actions initiated at integrin αvβ3 and involving, downstream, the EGFR-Ras signaling pathways.Entities:
Keywords: Colorectal Cancer; Epidermal growth factor receptor; Integrin αvβ3; NDAT; Ras mutation
Year: 2021 PMID: 33827580 DOI: 10.1186/s12929-021-00719-5
Source DB: PubMed Journal: J Biomed Sci ISSN: 1021-7770 Impact factor: 8.410